Press Releases Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
7.74 ^USD	+13.74%		+13.66%	+251.82%

07-02	Mesoblast to File Biological License Application with US FDA for Cellular Therapy	MT
07-01	Mesoblast to File Biologics License Application for Ryoncil	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MESOBLAST TO FILE BIOLOGIC LICENSE APPLICATION FOR RYONCIL FDA APPROVAL NEXT WEEK	07-02	AQ
Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week	07-01	AQ
Mesoblast Corporate Presentation at Investor Conference	06-02	AQ
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024	04-29	AQ
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK	03-28	AQ
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)	03-25	AQ
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer	03-13	AQ
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)	03-10	AQ
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023	02-28	AQ
Mesoblast Financial Results and Corporate Update Webcast	02-26	AQ
MESOBLAST - UNITED STATES FOOD & DRUG ADMINISTRATION GRANTS MESOBLAST ORPHAN-DRUG DESIGNATION FOR REVASCOR IN CHILDREN WITH CONGENITAL HEART DISEASE	02-15	AQ
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	02-14	AQ
MESOBLAST LIMITED - APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED DECEMBER 31, 2023	01-31	AQ
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023	01-30	AQ
MESOBLAST - UNITED STATES FOOD AND DRUG ADMINISTRATION GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR IN CHILDREN WITH CONGENITAL HEART DISEASE	01-19	AQ
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	01-18	AQ
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease	11-26	AQ
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD	11-21	AQ
MESOBLAST - APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED SEPTEMBER 30, 2023	23-10-31	AQ
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023	23-10-30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Mesoblast Limited Nasdaq

Equities

MESO

US5907174016

Press Releases

Filters